Jake Huneycutt is a former L/S Portfolio Manager, who developed one of the best long-term track records of outperformance in the US by investing in beaten-down, undervalued stocks. He is currently the Chief Content Creator for the data oriented website The New Madisonian. He holds an MBA in Finance from Emory University, a Master of Accounting from the University of North Carolina at Chapel Hill, and a B.A. in History from East Tennessee State University. Hobbies include hiking, trail running, karaoke, board games, classic films, and tournament poker. He is originally from Johnson City, TN and currently resides in Atlanta, GA.
If you have any questions about my research or any data related to my blogs, just inquire about them via comment. I am a 22 year old finance graduate from University of Pittsburgh. I have been studying the pharmaceutical industry for 5 years, and in particular, the top performing industries of Biotech and life science research. I research companies that target untapped markets and follow capital expenditure trends of the industry to capitalize on surrounding opportunities. Companies working with government funded research institutions (NIH, Foundations, Universities) are my favorite long picks. I am long small caps with strong pipelines and balance sheets, and short most one trick unicorns that don't have value or technical support. I pick my trades on a company by company basis. I don't always require that a company is involved in a favorable industry that has unmet demand by big pharma, but that is where I believe discrepancies in valuations occur most often. Recently, I have moved with momentum and enjoy testing hype in valuations. I use fundamental analysis, some historical pricing model techniques, and ultimately, macro themes to build and test my thesis's for industry analysis and trading. I always trade on technical analysis, but find value in fundamentals. In 2016, my Biotech industry top picks are involved in the clinical development of therapies in ophthalmology (Dry eye, DME, AMD), rare diseases (MF, Lupus, DMD), lung disorders (COPD), cardiovascular diseases (PAH, DCM, CLI), and breakthrough cancer therapies (so basically anything Celgene, Roche, and Novartis miss).
Expecting a lot of crowding in Melanoma (ex. ARRY) and cholesterol drugs (ex. $ESPR, $AEGR). I expect multiple expected drug launches to succeed and some to fail drastically. Finally, I am excited for biosimilars to make their debut in the market. Additionally, the PAH patent expirations for $UTHR and others in 2017/2018 and many more mAbs before 2019 should open up some serious entrants. I am still expecting a ton of BLAs to be filed 2016-2020 (ex. $SRNE,$IMMU,$SGEN). Thanks for reading, tweet @Kuritzmike if you want to see what I'm trading on the day to day.
I am a proprietary trader who focusses on both value and growth stocks as part of my long/short strategy. For investing, which I call long-term trading, I keenly observe moves made by activist investors and hedge funds. In my trading, I rely on quantitative analysis and algorithms. I trade any asset that exhibits significant momentum, is listed on an exchange and has ample liquidity, cryptocurrencies being one of them.
Why do I call 'investing' long-term trading? Because hiding behind a timeframe and hoping that it will tilt odds in your favor never works.